Disease-modifying therapeutic directions for lewy-body dementias

Frontiers in Neuroscience

Volumn 9, Issue AUG, 2015, Pages

  Zhang, Qiang ^a,b   Kim, Young Cho ^a   Narayanan, Nandakumar S ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Alzheimer's disease; Deep brain stimulation; Dementia with lewy bodies; Disease modifying therapy; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; NILOTINIB;

BRAIN DEPTH STIMULATION; DIFFUSE LEWY BODY DISEASE; DISEASE TRANSMISSION; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN TARGETING; RNA INTERFERENCE; SHORT SURVEY;

EID: 84940767660     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00293     Document Type: Short Survey

References (131)

1. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., et al. (2000). Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252. doi: 10.1016/S0896-6273(00)80886-7.
2. Aldavert-Vera, L., Huguet, G., Costa-Miserachs, D., Ortiz, S.P., Kádár, E., Morgado-Bernal, I., et al. (2013). Intracranial self-stimulation facilitates active-avoidance retention and induces expression of c-Fos and Nurr1 in rat brain memory systems. Behav. Brain Res. 250, 46-57. doi: 10.1016/j.bbr.2013.04.025.
3. Alvarez-Erviti, L., Seow, Y., Schapira, A.H., Gardiner, C., Sargent, I.L., Wood, M.J., et al. (2011). Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol. Dis. 42, 360-367. doi: 10.1016/j.nbd.2011.01.029.
4. Angot, E., Steiner, J.A., Hansen, C., Li, J.Y., and Brundin, P.;1. (2010). Are synucleinopathies prion-like disorders? Lancet Neurol. 9, 1128-1138. doi: 10.1016/S1474-4422(10)70213-1.
5. Angot, E., Steiner, J.A., Lema Tomé, C.M., Ekström, P., Mattsson, B., Björklund, A., et al. (2012). Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS ONE 7:e39465. doi: 10.1371/journal.pone.0039465.
6. Arrieta-Cruz, I., Pavlides, C., and Pasinetti, G.M. (2010). Deep brain stimulation in midline thalamic region facilitates synaptic transmission and shortterm memory in a mouse model of Alzheimer's Disease. Transl. Neurosci. 1, 188-194. doi: 10.2478/v10134-010-0023-x.
7. Bae, E.J., Lee, H.J., Rockenstein, E., Ho, D.H., Park, E.B., Yang, N.Y., et al. (2012). Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 32, 13454-13469. doi: 10.1523/JNEUROSCI. 1292-12.2012.
8. Barnikol, T.T., Pawelczyk, N.B., Barnikol, U.B., Kuhn, J., Lenartz, D., Sturm, V., et al. (2010). Changes in apraxia after deep brain stimulation of the nucleus basalis Meynert in a patient with Parkinson dementia syndrome. Mov. Disord. 25, 1519-1520. doi: 10.1002/mds.23141.
9. Berger, T.W., Hampson, R.E., Song, D., Goonawardena, A., Marmarelis, V.Z., and Deadwyler, S.A. (2011). A cortical neural prosthesis for restoring and enhancing memory. J. Neural Eng. 8:046017. doi: 10.1088/1741-2560/8/4/046017.
10. Blumberger, D.M., Mulsant, B.H., and Daskalakis, Z.J. (2013). What is the role of brain stimulation therapies in the treatment of depression? Curr. Psychiatry Rep. 15, 368. doi: 10.1007/s11920-013-0368-1.
11. Boix-Trelis, N., Vale-Martínez, A., Guillazo-Blanch, G., Costa-Miserachs, D., and Martí-Nicolovius, M. (2006). Effects of nucleus basalis magnocellularis stimulation on a socially transmitted food preference and c-Fos expression. Learn. Mem. 13, 783-793. doi: 10.1101/lm.305306.
12. Boix-Trelis, N., Vale-Martinez, A., Guillazo-Blanch, G., and Marti-Nicolovius, M. (2009). Induction of c-Fos expression by electrical stimulation of the nucleus basalis magnocellularis. Neurosci. Lett. 449, 137-141. doi: 10.1016/j.neulet.2008.10.105.
13. Borghi, R., Marchese, R., Negro, A., Marinelli, L., Forloni, G., Zaccheo, D., et al. (2000). Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287, 65-67. doi: 10.1016/S0304-3940(00)01153-8.
14. Boström, F., Jönsson, L., Minthon, L., and Londos, E. (2007). Patients with Lewy body dementia use more resources than those with Alzheimer's disease. Int. J. Geriatr. Psychiatry 22, 713-719. doi: 10.1002/gps.1738.
15. Braak, H., Del Tredici, K., Rub, U., De Vos, R.A., Jansen Steur, E.N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211. doi: 10.1016/S0197-4580(02)00065-9.
16. Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R., and Sudhof, T.C. (2010). Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663-1667. doi: 10.1126/science.1195227.
17. Chen, N., Dong, S., Yan, T., Yan, N., Ma, Y., and Yu, C. (2014). High-frequency stimulation of anterior nucleus thalamus improves impaired cognitive function induced by intra-hippocampal injection of Abeta1-40 in rats. Chin. Med. J. 127, 125-129. doi: 10.3760/cma.j.issn.0366-6999.20131025.
18. Chen, P.E., Specht, C.G., Morris, R.G., and Schoepfer, R. (2002). Spatial learning is unimpaired in mice containing a deletion of the alpha-synuclein locus. Eur. J. Neurosci. 16, 154-158. doi: 10.1046/j.1460-9568.2002.02062.x.
19. Cheng, F., Vivacqua, G., and Yu, S. (2011). The role of alpha-synuclein in neurotransmission and synaptic plasticity. J. Chem. Neuroanat. 42, 242-248. doi: 10.1016/j.jchemneu.2010.12.001.
20. Danzer, K.M., Kranich, L.R., Ruf, W.P., Cagsal-Getkin, O., Winslow, A.R., Zhu, L., et al. (2012). Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7:42. doi: 10.1186/1750-1326-7-42.
21. Danzer, K.M., Ruf, W.P., Putcha, P., Joyner, D., Hashimoto, T., Glabe, C., et al. (2011). Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J. 25, 326-336. doi: 10.1096/fj.10-164624.
22. Desplats, P., Lee, H.J., Bae, E.J., Patrick, C., Rockenstein, E., Crews, L., et al. (2009). Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U.S.A. 106, 13010-13015. doi: 10.1073/pnas.0903691106.
23. Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., et al. (2006). A randomized trial of deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 355, 896-908. doi: 10.1056/NEJMoa060281.
24. El-Agnaf, O.M., Paleologou, K.E., Greer, B., Abogrein, A.M., King, J.E., Salem, S.A., et al. (2004). A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J. 18, 1315-1317. doi: 10.1096/fj.03-1346fje.
25. El-Agnaf, O.M., Salem, S.A., Paleologou, K.E., Cooper, L.J., Fullwood, N.J., Gibson, M.J., et al. (2003). Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17, 1945-1947. doi: 10.1096/fj.03-0098fje.
26. Elbaz, A., Clavel, J., Rathouz, P.J., Moisan, F., Galanaud, J.P., Delemotte, B., et al. (2009). Professional exposure to pesticides and Parkinson disease. Ann. Neurol. 66, 494-504. doi: 10.1002/ana.21717.
27. Emmanouilidou, E., Elenis, D., Papasilekas, T., Stranjalis, G., Gerozissis, K., Ioannou, P.C., et al. (2011). Assessment of alpha-synuclein secretion in mouse and human brain parenchyma. PLoS ONE 6:e22225. doi: 10.1371/journal.pone.0022225.
28. Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S.D., Ntzouni, M., Margaritis, L.H., et al. (2010). Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 30, 6838-6851. doi: 10.1523/JNEUROSCI. 5699-09.2010.
29. Fell, J., Staresina, B.P., Do Lam, A.T., Widman, G., Helmstaedter, C., Elger, C.E., et al. (2013). Memory modulation by weak synchronous deep brain stimulation: a pilot study. Brain Stimul. 6, 270-273. doi: 10.1016/j.brs.2012.08.001.
30. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811.
31. Follett, K.A., Weaver, F.M., Stern, M., Hur, K., Harris, C.L., Luo, P., et al. (2010). Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 362, 2077-2091. doi: 10.1056/NEJMoa0907083.
32. Freund, H.J., Kuhn, J., Lenartz, D., Mai, J.K., Schnell, T., Klosterkoetter, J., et al. (2009). Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation. Arch. Neurol. 66, 781-785. doi: 10.1001/archneurol.2009.102.
33. Freundt, E.C., Maynard, N., Clancy, E.K., Roy, S., Bousset, L., Sourigues, Y., et al. (2012). Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann. Neurol. 72, 517-524. doi: 10.1002/ana.23747.
34. Galvin, J.E., and Balasubramaniam, M. (2013). Lewy body dementia: the under-recognized but common FOE. Cerebrum 2013, 13.
35. George, S., Rey, N.L., Reichenbach, N., Steiner, J.A., and Brundin, P. (2013). alpha-Synuclein: the long distance runner. Brain Pathol. 23, 350-357. doi: 10.1111/bpa.12046.
36. Goedert, M., Spillantini, M.G., Del Tredici, K., and Braak, H. (2013). 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13-24. doi: 10.1038/nrneurol.2012.242.
37. Hallett, P.J., Cooper, O., Sadi, D., Robertson, H., Mendez, I., and Isacson, O. (2014). Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. Cell Rep. 7, 1755-1761. doi: 10.1016/j.celrep.2014.05.027.
38. Hamani, C., Stone, S.S., Garten, A., Lozano, A.M., and Winocur, G. (2011). Memory rescue and enhanced neurogenesis following electrical stimulation of the anterior thalamus in rats treated with corticosterone. Exp. Neurol. 232, 100-104. doi: 10.1016/j.expneurol.2011.08.023.
39. Han, Y., Khodr, C.E., Sapru, M.K., Pedapati, J., and Bohn, M.C. (2011). A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons. Brain Res. 1386, 15-24. doi: 10.1016/j.brainres.2011.02.041.
40. Hansen, C., Angot, E., Bergström, A.L., Steiner, J.A., Pieri, L., Paul, G., et al. (2011). alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715-725. doi: 10.1172/JCI43366.
41. Hardenacke, K., Shubina, E., Buhrle, C.P., Zapf, A., Lenartz, D., Klosterkötter, J., et al. (2013). Deep brain stimulation as a tool for improving cognitive functioning in Alzheimer's dementia: a systematic review. Front. Psychiatry 4:159. doi: 10.3389/fpsyt.2013.00159.
42. Hasegawa, T., Konno, M., Baba, T., Sugeno, N., Kikuchi, A., Kobayashi, M., et al. (2011). The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of alpha-synuclein. PLoS ONE 6:e29460. doi: 10.1371/journal.pone.0029460.
43. Hayashita-Kinoh, H., Yamada, M., Yokota, T., Mizuno, Y., and Mochizuki, H. (2006). Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem. Biophys. Res. Commun. 341, 1088-1095. doi: 10.1016/j.bbrc.2006.01.057.
44. Hebron, M.L., Lonskaya, I., and Moussa, C.E. (2013). Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. Hum. Mol. Genet. 22, 3315-3328. doi: 10.1093/hmg/ddt192.
45. Heidebrink, J.L. (2002). Is dementia with Lewy bodies the second most common cause of dementia? J. Geriatr. Psychiatry Neurol. 15, 182-187. doi: 10.1177/089198870201500402.
46. Herva, M.E., Zibaee, S., Fraser, G., Barker, R.A., Goedert, M., and Spillantini, M.G. (2014). Anti-amyloid compounds inhibit alpha-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA). J. Biol. Chem. 289, 11897-11905. doi: 10.1074/jbc.M113.542340.
47. Hescham, S., Lim, L.W., Jahanshahi, A., Steinbusch, H.W., Prickaerts, J., Blokland, A., et al. (2013). Deep brain stimulation of the forniceal area enhances memory functions in experimental dementia: the role of stimulation parameters. Brain Stimul. 6, 72-77. doi: 10.1016/j.brs.2012.01.008.
48. Hotta, H., Kagitani, F., Kondo, M., and Uchida, S. (2009). Basal forebrain stimulation induces NGF secretion in ipsilateral parietal cortex via nicotinic receptor activation in adult, but not aged rats. Neurosci. Res. 63, 122-128. doi: 10.1016/j.neures.2008.11.004.
49. Hotta, H., Uchida, S., and Kagitani, F. (2007). Stimulation of the nucleus basalis of Meynert produces an increase in the extracellular release of nerve growth factor in the rat cerebral cortex. J. Physiol. Sci. 57, 383-387. doi: 10.2170/physiolsci.SC008107.
50. Huguet, G., Aldavert-Vera, L., Kádár, E., Peña De Ortiz, S., Morgado-Bernal, I., and Segura-Torres, P. (2009). Intracranial self-stimulation to the lateral hypothalamus, a memory improving treatment, results in hippocampal changes in gene expression. Neuroscience 162, 359-374. doi: 10.1016/j.neuroscience.2009.04.074.
51. Isacson, O., Seo, H., Lin, L., Albeck, D., and Granholm, A.C. (2002). Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci. 25, 79-84. doi: 10.1016/S0166-2236(02)02037-4.
52. Jang, A., Lee, H.J., Suk, J.E., Jung, J.W., Kim, K.P., and Lee, S.J. (2010). Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J. Neurochem. 113, 1263-1274. doi: 10.1111/j.1471-4159.2010.06695.x.
53. Jensen, P.H., Li, J.Y., Dahlström, A., and Dotti, C.G. (1999). Axonal transport of synucleins is mediated by all rate components. Eur. J. Neurosci. 11, 3369-3376.
54. Jeong Da, U., Lee, J.E., Lee, S.E., Chang, W.S., Kim, S.J., and Chang, J.W. (2014). Improvements in memory after medial septum stimulation are associated with changes in hippocampal cholinergic activity and neurogenesis. Biomed. Res. Int. 2014:568587. doi: 10.1155/2014/568587.
55. Jiang, M., Porat-Shliom, Y., Pei, Z., Cheng, Y., Xiang, L., Sommers, K., et al. (2010). Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism. J. Neurochem. 114, 419-429. doi: 10.1111/j.1471-4159.2010.06752.x.
56. Junn, E., Lee, K.W., Jeong, B.S., Chan, T.W., Im, J.Y., and Mouradian, M.M. (2009). Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. U.S.A. 106, 13052-13057. doi: 10.1073/pnas.0906277106.
57. Kadar, E., Aldavert-Vera, L., Huguet, G., Costa-Miserachs, D., Morgado-Bernal, I., and Segura-Torres, P. (2011). Intracranial self-stimulation induces expression of learning and memory-related genes in rat amygdala. Genes Brain Behav. 10, 69-77. doi: 10.1111/j.1601-183X. 2010.00609.x.
58. Khodr, C.E., Becerra, A., Han, Y., and Bohn, M.C. (2014). Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Brain Res. 1550, 47-60. doi: 10.1016/j.brainres.2014.01.010.
59. Khodr, C.E., Sapru, M.K., Pedapati, J., Han, Y., West, N.C., Kells, A.P., et al. (2011). An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res. 1395, 94-107. doi: 10.1016/j.brainres.2011.04.036.
60. Kilgard, M.P., and Merzenich, M.M. (1998). Cortical map reorganization enabled by nucleus basalis activity. Science 279, 1714-1718.
61. Kokhan, V.S., Afanasyeva, M.A., and Van'kin, G.I. (2012). Alpha-Synuclein knockout mice have cognitive impairments. Behav. Brain Res. 231, 226-230. doi: 10.1016/j.bbr.2012.03.026.
62. Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B., and Olanow, C.W. (2008). Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504-506. doi: 10.1038/nm1747.
63. Kordower, J.H., Dodiya, H.B., Kordower, A.M., Terpstra, B., Paumier, K., Madhavan, L., et al. (2011). Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol. Dis. 43, 552-557. doi: 10.1016/j.nbd.2011.05.001.
64. Kuhn, J., Hardenacke, K., Lenartz, D., Gruendler, T., Ullsperger, M., Bartsch, C., et al. (2015). Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer's dementia. Mol. Psychiatry 20, 353-360. doi: 10.1038/mp.2014.32.
65. Laxton, A.W., Tang-Wai, D.F., McAndrews, M.P., Zumsteg, D., Wennberg, R., Keren, R., et al. (2010). A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann. Neurol. 68, 521-534. doi: 10.1002/ana.22089.
66. Lee, H.J., Bae, E.J., and Lee, S.J. (2014). Extracellular alpha-synuclein-a novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 10, 92-98. doi: 10.1038/nrneurol.2013.275.
67. Lee, H.J., Patel, S., and Lee, S.J. (2005). Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25, 6016-6024. doi: 10.1523/JNEUROSCI. 0692-05.2005.
68. Lewis, J., Melrose, H., Bumcrot, D., Hope, A., Zehr, C., Lincoln, S., et al. (2008). In vivo silencing of alpha-synuclein using naked siRNA. Mol. Neurodegener. 3:19. doi: 10.1186/1750-1326-3-19.
69. LeWitt, P.A., Rezai, A.R., Leehey, M.A., Ojemann, S.G., Flaherty, A.W., Eskandar, E.N., et al. (2011). AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10, 309-319. doi: 10.1016/S1474-4422(11)70039-4.
70. Li, J.Y., Englund, E., Holton, J.L., Soulet, D., Hagell, P., Lees, A.J., et al. (2008). Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501-503. doi: 10.1038/nm1746.
71. Lippa, C.F., Duda, J.E., Grossman, M., Hurtig, H.I., Aarsland, D., Boeve, B.F., et al. (2007). DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68, 812-819. doi: 10.1212/01.wnl.0000256715.13907.d3.
72. Liu, J., Zhang, J.P., Shi, M., Quinn, T., Bradner, J., Beyer, R., et al. (2009). Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J. Neurosci. 29, 1480-1485. doi: 10.1523/JNEUROSCI. 6202-08.2009.
73. Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O'brien, P., Trojanowski, J.Q., et al. (2012a). Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953. doi: 10.1126/science.1227157.
74. Luk, K.C., Kehm, V.M., Zhang, B., O'brien, P., Trojanowski, J.Q., and Lee, V.M. (2012b). Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J. Exp. Med. 209, 975-986. doi: 10.1084/jem.20112457.
75. Lynch, S.M., Zhou, C., and Messer, A. (2008). An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J. Mol. Biol. 377, 136-147. doi: 10.1016/j.jmb.2007.11.096.
76. Magen, I., Fleming, S.M., Zhu, C., Garcia, E.C., Cardiff, K.M., Dinh, D., et al. (2012). Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. Eur. J. Neurosci. 35, 870-882. doi: 10.1111/j.1460-9568.2012.08012.x.
77. Mahul-Mellier, A.L., Fauvet, B., Gysbers, A., Dikiy, I., Oueslati, A., Georgeon, S., et al. (2014). c-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum. Mol. Genet. 23, 2858-2879. doi: 10.1093/hmg/ddt674.
78. Mair, R.G., and Hembrook, J.R. (2008). Memory enhancement with event-related stimulation of the rostral intralaminar thalamic nuclei. J. Neurosci. 28, 14293-14300. doi: 10.1523/JNEUROSCI. 3301-08.2008.
79. Mandler, M., Valera, E., Rockenstein, E., Weninger, H., Patrick, C., Adame, A., et al. (2014). Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol. 127, 861-879. doi: 10.1007/s00401-014-1256-4.
80. Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., et al. (2005). Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857-868. doi: 10.1016/j.neuron.2005.05.010.
81. Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., et al. (2011). Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 6:e19338. doi: 10.1371/journal.pone.0019338.
82. Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., et al. (2001). beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 98, 12245-12250. doi: 10.1073/pnas.211412398.
83. Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., et al. (2013). Prion-like spreading of pathological alpha-synuclein in brain. Brain 136, 1128-1138. doi: 10.1093/brain/awt037.
84. Mayo, M.C., and Bordelon, Y. (2014). Dementia with Lewy bodies. Semin. Neurol. 34, 182-188. doi: 10.1055/s-0034-1381741.
85. McCormack, A.L., Mak, S.K., Henderson, J.M., Bumcrot, D., Farrer, M.J., and Di Monte, D.A. (2010). Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS ONE 5:e12122. doi: 10.1371/journal.pone.0012122.
86. Merdes, A.R., Hansen, L.A., Jeste, D.V., Galasko, D., Hofstetter, C.R., Ho, G.J., et al. (2003). Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60, 1586-1590. doi: 10.1212/01.WNL. 0000065889.42856.F2.
87. Mollenhauer, B., Trautmann, E., Otte, B., Ng, J., Spreer, A., Lange, P., et al. (2012). Alpha-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J. Neural Transm. 119, 739-746. doi: 10.1007/s00702-012-0784-0.
88. Mougenot, A.L., Nicot, S., Bencsik, A., Morignat, E., Verchére, J., Lakhdar, L., et al. (2012). Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225-2228. doi: 10.1016/j.neurobiolaging.2011.06.022.
89. Mullin, S., and Schapira, A. (2013). a-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol. Neurobiol. 47, 587-597. doi: 10.1007/s12035-013-8394-x.
90. Narayanan, N.S., Rodnitzky, R.L., and Uc, E.Y. (2013). Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. Rev. Neurosci. 24, 267-278. doi: 10.1515/revneuro-2013-0004.
91. Narkiewicz, J., Giachin, G., and Legname, G. (2014). In vitro aggregation assays for the characterization of alpha-synuclein prion-like properties. Prion 8, 19-32. doi: 10.4161/pri.28125.
92. Nemani, V.M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M.K., et al. (2010). Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66-79. doi: 10.1016/j.neuron.2009.12.023.
93. Oh, Y.S., Kim, H.J., Lee, K.J., Kim, Y.I., Lim, S.C., and Shon, Y.M. (2012). Cognitive improvement after long-term electrical stimulation of bilateral anterior thalamic nucleus in refractory epilepsy patients. Seizure 21, 183-187. doi: 10.1016/j.seizure.2011.12.003.
94. Overk, C.R., and Masliah, E. (2014). Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem. Pharmacol. 88, 508-516. doi: 10.1016/j.bcp.2014.01.015.
95. Pan-Montojo, F., Schwarz, M., Winkler, C., Arnhold, M., O'sullivan, G.A., Pal, A., et al. (2012). Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci. Rep. 2:898. doi: 10.1038/srep00898.
96. Parker, K.L., Lamichhane, D., Caetano, M.S., and Narayanan, N.S. (2013). Executive dysfunction in Parkinson's disease and timing deficits. Front. Integr. Neurosci. 7:75. doi: 10.3389/fnint.2013.00075.
97. Plow, E.B., Pascual-Leone, A., and Machado, A. (2012). Brain stimulation in the treatment of chronic neuropathic and non-cancerous pain. J. Pain 13, 411-424. doi: 10.1016/j.jpain.2012.02.001.
98. Recasens, A., Dehay, B., Bové, J., Carballo-Carbajal, I., Dovero, S., Pérez-Villalba, A., et al. (2014). Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75, 351-362. doi: 10.1002/ana.24066.
99. Rey, N.L., Petit, G.H., Bousset, L., Melki, R., and Brundin, P. (2013). Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol. 126, 555-573. doi: 10.1007/s00401-013-1160-3.
100. Reyes, J.F., Rey, N.L., Bousset, L., Melki, R., Brundin, P., and Angot, E. (2014). Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 62, 387-398. doi: 10.1002/glia.22611.
101. Rezai, A.R., Machado, A.G., Deogaonkar, M., Azmi, H., Kubu, C., and Boulis, N.M. (2008). Surgery for movement disorders. Neurosurgery 62 (Suppl. 2), 809-838; discussion 838-809. doi: 10.1227/01.neu.0000316285.52865.53.
102. Ricci, M., Guidoni, S.V., Sepe-Monti, M., Bomboi, G., Antonini, G., Blundo, C., et al. (2009). Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Arch. Gerontol. Geriatr. 49, e101-e104. doi: 10.1016/j.archger.2008.10.001.
103. Rochet, J.C. (2007). Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev. Mol. Med. 9, 1-34. doi: 10.1017/S1462399407000385.
104. Ruiz-Medina, J., Morgado-Bernal, I., Redolar-Ripoll, D., Aldavert-Vera, L., and Segura-Torres, P. (2008a). Intracranial self-stimulation facilitates a spatial learning and memory task in the Morris water maze. Neuroscience 154, 424-430. doi: 10.1016/j.neuroscience.2008.03.059.
105. Ruiz-Medina, J., Redolar-Ripoll, D., Morgado-Bernal, I., Aldavert-Vera, L., and Segura-Torres, P. (2008b). Intracranial self-stimulation improves memory consolidation in rats with little training. Neurobiol. Learn. Mem. 89, 574-581. doi: 10.1016/j.nlm.2007.11.005.
106. Sacino, A.N., Brooks, M., Mcgarvey, N.H., Mckinney, A.B., Thomas, M.A., Levites, Y., et al. (2013). Induction of CNS alpha-synuclein pathology by fibrillar and non-amyloidogenic recombinant alpha-synuclein. Acta Neuropathol. Commun. 1:38. doi: 10.1186/2051-5960-1-38.
107. Sankar, T., Lipsman, N., and Lozano, A.M. (2014). Deep brain stimulation for disorders of memory and cognition. Neurotherapeutics 11, 527-534. doi: 10.1007/s13311-014-0275-0.
108. Sapru, M.K., Yates, J.W., Hogan, S., Jiang, L., Halter, J., and Bohn, M.C. (2006). Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol. 198, 382-390. doi: 10.1016/j.expneurol.2005.12.024.
109. Shah, S.A., Baker, J.L., Ryou, J.W., Purpura, K.P., and Schiff, N.D. (2009). Modulation of arousal regulation with central thalamic deep brain stimulation. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2009, 3314-3317. doi: 10.1109/iembs.2009.5333751.
110. Shirvalkar, P., Seth, M., Schiff, N.D., and Herrera, D.G. (2006). Cognitive enhancement with central thalamic electrical stimulation. Proc. Natl. Acad. Sci. U.S.A. 103, 17007-17012. doi: 10.1073/pnas.0604811103.
111. Sibley, C.R., Seow, Y., Curtis, H., Weinberg, M.S., and Wood, M.J. (2012). Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224. Nucleic Acids Res. 40, 9863-9875. doi: 10.1093/nar/gks712.
112. Smith, A.C., Shah, S.A., Hudson, A.E., Purpura, K.P., Victor, J.D., Brown, E.N., et al. (2009). A Bayesian statistical analysis of behavioral facilitation associated with deep brain stimulation. J. Neurosci. Methods 183, 267-276. doi: 10.1016/j.jneumeth.2009.06.028.
113. Soriano-Mas, C., Redolar-Ripoll, D., Aldavert-Vera, L., Morgado-Bernal, I., and Segura-Torres, P. (2005). Post-training intracranial self-stimulation facilitates a hippocampus-dependent task. Behav. Brain Res. 160, 141-147. doi: 10.1016/j.bbr.2004.11.025.
114. Soriano-Mas, C., Redolar-Ripoll, D., Guillazo-Blanch, G., Morgado-Bernal, I., and Segura-Torres, P. (2007). Intracranial self-stimulation after memory reactivation: immediate and late effects. Brain Res. Bull. 74, 51-57. doi: 10.1016/j.brainresbull.2007.05.003.
115. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M., and Goedert, M. (1998). alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 95, 6469-6473.
116. Stefani, A., Pierantozzi, M., Ceravolo, R., Brusa, L., Galati, S., and Stanzione, P. (2010). Deep brain stimulation of pedunculopontine tegmental nucleus (PPTg) promotes cognitive and metabolic changes: a target-specific effect or response to a low-frequency pattern of stimulation? Clin. EEG Neurosci. 41, 82-86. doi: 10.1177/155005941004100207.
117. Stone, S.S., Teixeira, C.M., Devito, L.M., Zaslavsky, K., Josselyn, S.A., Lozano, A.M., et al. (2011). Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory. J. Neurosci. 31, 13469-13484. doi: 10.1523/JNEUROSCI. 3100-11.2011.
118. Suthana, N., Haneef, Z., Stern, J., Mukamel, R., Behnke, E., Knowlton, B., et al. (2012). Memory enhancement and deep-brain stimulation of the entorhinal area. N. Engl. J. Med. 366, 502-510. doi: 10.1056/NEJMoa1107212.
119. Tran, H.T., Chung, C.H., Iba, M., Zhang, B., Trojanowski, J.Q., Luk, K.C., et al. (2014). Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep. 7, 2054-2065. doi: 10.1016/j.celrep.2014.05.033.
120. Turnbull, I.M., McGeer, P.L., Beattie, L., Calne, D., and Pate, B. (1985). Stimulation of the basal nucleus of Meynert in senile dementia of Alzheimer's type. A preliminary report. Appl. Neurophysiol. 48, 216-221.
121. Valera, E., and Masliah, E. (2013). Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies. Pharmacol. Ther. 138, 311-322. doi: 10.1016/j.pharmthera.2013.01.013.
122. Voges, J., Waerzeggers, Y., Maarouf, M., Lehrke, R., Koulousakis, A., Lenartz, D., et al. (2006). Deep-brain stimulation: long-term analysis of complications caused by hardware and surgery-experiences from a single centre. J. Neurol. Neurosurg. Psychiatr. 77, 868-872. doi: 10.1136/jnnp.2005.081232.
123. Volpicelli-Daley, L.A., Luk, K.C., Patel, T.P., Tanik, S.A., Riddle, D.M., Stieber, A., et al. (2011). Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57-71. doi: 10.1016/j.neuron.2011.08.033.
124. Wagner, J., Ryazanov, S., Leonov, A., Levin, J., Shi, S., Schmidt, F., et al. (2013). Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 125, 795-813. doi: 10.1007/s00401-013-1114-9.
125. Watts, J.C., Giles, K., Oehler, A., Middleton, L., Dexter, D.T., Gentleman, S.M., et al. (2013). Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 110, 19555-19560. doi: 10.1073/pnas.1318268110.
126. Williams, Z.M., and Eskandar, E.N. (2006). Selective enhancement of associative learning by microstimulation of the anterior caudate. Nat. Neurosci. 9, 562-568. doi: 10.1038/nn1662.
127. Wood, S.J., Wypych, J., Steavenson, S., Louis, J.C., Citron, M., and Biere, A.L. (1999). alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509-19512.
128. Yuan, B., and Sierks, M.R. (2009). Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells. Neurosci. Lett. 459, 16-18. doi: 10.1016/j.neulet.2009.04.046.
129. Zaltieri, M., Longhena, F., Pizzi, M., Missale, C., Spano, P., and Bellucci, A. (2015). Mitochondrial dysfunction and alpha-synuclein synaptic pathology in Parkinson's Disease: who's on first? Parkinsons. Dis. 2015:108029. doi: 10.1155/2015/108029.
130. Zhou, C., Emadi, S., Sierks, M.R., and Messer, A. (2004). A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol. Ther. 10, 1023-1031. doi: 10.1016/j.ymthe.2004.08.019.
131. Zhou, W., Bercury, K., Cummiskey, J., Luong, N., Lebin, J., and Freed, C.R. (2011). Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J. Biol. Chem. 286, 14941-14951. doi: 10.1074/jbc.M110.211029.